Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + sintilimab + bevacizumab versus control in previously treated MSS/pMMR advanced colorectal cancer
CTR20242806Phase 3Active
- Sponsor
- Chipscreen Biosciences
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tucidinostat, sintilimab, bevacizumab in colorectal cancer (CRC), sponsored by Chipscreen Biosciences. Started Dec 2024; status: active.
02
Drugs
tucidinostatsintilimabbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20242806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242806.